Dysregulations in Autoimmune Regulator (AIRE) in Controlling B and T Cell Tolerance Have Important Implications for a Broad Range of Dermatologic Diseases

Abstract

Keywords

APECED melanoma denosumab immune checkpoint inhibitors

Get full access to this article

View all access options for this article.

References

Sng

Ayoglu

Chen

et al. Aire expression controls the peripheral selection of autoreactive B cells. Sci Immunol. 2019;4(34):eaav6778.doi:10.1126/sciimmunol.aav6778

Bakhru

Zhu

M-L.

Wang

H-H

et al. Combination central tolerance and peripheral checkpoint blockade unleashes antimelanoma immunity. JCI Insight. 2017;2(18). doi:10.1172/jci.insight.93265

Khan

IS.

Mouchess

ML.

Zhu

M-L

et al. Enhancement of an anti-tumor immune response by transient blockade of central T cell tolerance. J Exp Med. 2014;211(5):761-768.doi:10.1084/jem.20131889

U.S. National Library of Medicine . Evaluation of denosumab in combination with immune checkpoint inhibitors in patients with unresectable or metastatic melanoma (CHARLI). U.S. National Library of Medicine. https://clinicaltrials.gov/c t2/show/NCT03161756?term=denosumab&cond=Melanma&rank=1. Accessed September 2019.

U.S. National Library of Medicine . Denosumab + PD-1 in subjects with stage III/IV Melanoma. U.S. National Library of Medicine. https://clinicaltrials.gov/ct2/show/N CT03620019?term=denosumab&rank=9. Published. Accessed September 2019.